TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24326088

Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices (MADs)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MADs
Number of subjects: 19
Study: 21131389

Group type: EXPERIMENTAL
Intervention: 3D cone beam computed tomography (CBCT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional two-dimensional (2D) images
Number of subjects: 27
Study: 19403229

Group type: EXPERIMENTAL
Intervention: CPP-ACP-containing paste
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Time below pH 5.7 and time to return to resting pH
Number of subjects: 15
Study: 18334764

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 12
Study: 15562056

Group type: EXPERIMENTAL
Intervention: IV lidocaine 1.5 mg/kg
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 502
Study: 11352682

Group type: EXPERIMENTAL
Intervention: Serum elastin peptides (EP) and procollagen‐IIIN‐terminal propeptide (PIIINP) measured in ng/ml using ELISA and RIA techniques.
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Predictive model including EP, PIIINP, and initial AAA size.
Number of subjects: 141
Study: 9135021

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with 5-fluorouracil plus levamisole
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Low-level c-myc amplification
Number of subjects: 149

Group type: COMPARATOR
Intervention: c-myc status
Number of subjects: 149
Study: 7523647

Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (12.8 mg iron per liter)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Regular formula (1.1 mg iron per liter)
Number of subjects: 283
Study: 3061771

Group type: EXPERIMENTAL
Intervention: Artificial surfactant (ALEC)
Number of subjects: 341
Study: 31836609

Group type: EXPERIMENTAL
Intervention: Capivasertib 480 mg b.i.d.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Capivasertib 360 mg b.i.d.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Capivasertib 240 mg b.i.d.
Number of subjects: 28
Study: 28703440

Group type: EXPERIMENTAL
Intervention: Face-to-face education for 35 participants for 60 minutes
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standardized materials for 35 participants for 20 minutes
Number of subjects: 70
Study: 28473524

Group type: EXPERIMENTAL
Intervention: Mailed deprescribing brochure on benzodiazepines
Number of subjects: 261
Study: 26163281

Group type: EXPERIMENTAL
Intervention: Lateralized RSA
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-lateralized RSA
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 23252791

Group type: EXPERIMENTAL
Intervention: Pineapple
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Banana
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Orange
Number of subjects: 30
Study: 20970117

Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intensive DBT training
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Additional six months of DBT
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 43
Study: 17919346

Group type: EXPERIMENTAL
Intervention: Himalaya 292 foods
Number of subjects: 17
Study: 16325898

Group type: EXPERIMENTAL
Intervention: Daily sunscreen use
Number of subjects: 1621

Group type: COMPARATOR
Intervention: Discretionary sunscreen use
Number of subjects: 1621
Study: 12843357

Group type: EXPERIMENTAL
Intervention: Acute stroke patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Common haplotype A-G-8/12-C
Number of subjects: 48
Study: 10068383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: CEE plus cyclic medroxyprogesterone acetate (MPA)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: CEE plus daily MPA
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: CEE plus cyclic micronized progesterone (MP)
Number of subjects: 307
Study: 8843810

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Severe malaria
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall incidence of PMNS
Number of subjects: 18
Study: 1704026

Group type: EXPERIMENTAL
Intervention: Cold glucose solution (5 degrees C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Warm glucose solution (50 degrees C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 15
Study: 6660202

Group type: EXPERIMENTAL
Intervention: Acupuncture on the normal side (including points Chu‐chih (LI‐11), Shou‐son‐li (LI‐10), Wai‐kuan (TH‐5), Ho‐ku (LI‐4), Yang‐chih (TH‐4)) followed by rehabilitation (Reha) of the lesion.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy of Reha of the lesion with acupuncture on the abnormal side (including points Chu‐chih (LI‐11), Shou‐san‐li (LI‐10), Wai‐kuan (TH‐5), Ho‐ku (LI‐4), Yang‐chih (TH‐4)).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple treatment with Reha on the abnormal side.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple treatment with acupuncture on the abnormal side.
Number of subjects: 0
Study: 30037491

Group type: EXPERIMENTAL
Intervention: CPT‐11 (irinotecan hydrochloride) administered at a dosage of 100 mg/m2 via intravenous infusion on days 1, 8, and 15 of a 4-week cycle, for up to 2 cycles.
Number of subjects: 22
Study: 27307314

Group type: EXPERIMENTAL
Intervention: Hydrolysed chicken liver diet (HZD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydrolysed poultry feather diet (RCU)
Number of subjects: 10
Study: 24642950

Group type: EXPERIMENTAL
Intervention: Sucrose-sweetened low-fat milk at 10% or 20% of calories
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HFCS-sweetened low-fat milk at 10% or 20% of calories
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Eucaloric diet with added sugars (sucrose or HFCS)
Number of subjects: 65
Study: 22433300

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75-mg lozenges (test drug)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flurbiprofen 8.75-mg lozenges (reference drug)
Number of subjects: 12
Study: 20694731

Group type: EXPERIMENTAL
Intervention: Cooling collar (CC(90))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cooling collar (CC(15))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Uncooled collar (C(90))
Number of subjects: 17

Group type: COMPARATOR
Intervention: No collar (NC(90))
Number of subjects: 17

Group type: COMPARATOR
Intervention: No collar (NC(15))
Number of subjects: 17
Study: 17987285

Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice on the first day and 200 mg twice on the second day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg once on the first day and 200 mg once on the second day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (5 microg/kg of intravenous fentanyl without pretreatment)
Number of subjects: 12
Study: 15782792

Group type: EXPERIMENTAL
Intervention: Right subaxillary muscle-sparing thoracotomy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Right thoracotomy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Midline sternotomy
Number of subjects: 161
Study: 12391036

Group type: EXPERIMENTAL
Intervention: Exercise (1 hour cycling)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Coffee ingestion (5 mg caffeine/kg body mass)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Coffee ingestion followed by exercise (1 hour later)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (did nothing)
Number of subjects: 13
Study: 11209671

Group type: EXPERIMENTAL
Intervention: Mild cold stress (16 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermoneutral conditions (28 degrees C)
Number of subjects: 0
Study: 9135468

Group type: EXPERIMENTAL
Intervention: Oral metoclopramide administered 90 min prior to barium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard practice of metoclopramide 5-10 min prior to barium)
Number of subjects: 0
Study: 1398229

Group type: EXPERIMENTAL
Intervention: Psyllium (10.8 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3892172

Group type: EXPERIMENTAL
Intervention: Crystalloid prime containing glucose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Crystalloid prime containing lactate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Crystalloid prime containing glucose and lactate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Crystalloid prime containing neither glucose nor lactate
Number of subjects: 24
Study: 31577682

Group type: EXPERIMENTAL
Intervention: Risk-stratification system based on significant risk factors (age, sex, COPD, diabetes, anemia, end-stage renal disease)
Number of subjects: 7582

Group type: EXPERIMENTAL
Intervention: Risk-stratification system applied to validation cohort
Number of subjects: 7582
Study: 30427805

Group type: EXPERIMENTAL
Intervention: Visual attention manipulation (looking toward and away from the hand)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cognitive regulation (rest, attenuate MEP amplitude, potentiate MEP amplitude)
Number of subjects: 20
Study: 26752327

Group type: EXPERIMENTAL
Intervention: Panic‐smoking Program (PSP)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 526
Study: 25352208

Group type: EXPERIMENTAL
Intervention: echocardiographic calcium score (eCS)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: non-coronary cardiac calcium score (nCACS)
Number of subjects: 141
Study: 22633178

Group type: EXPERIMENTAL
Intervention: Educational and environmental intervention (weekly nutrition and food classes and food environment changes)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 103
Study: 20045366

Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca) for 12 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca) for 24 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca) for >or= 12 months
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca) for >or= 1 dose
Number of subjects: 29
Study: 18435668

Group type: EXPERIMENTAL
Intervention: Sulphonylurea therapy
Number of subjects: 1364
Study: 15974563

Group type: EXPERIMENTAL
Intervention: etoricoxib (60 mg, 90 mg, or 120 mg)
Number of subjects: 5441

Group type: COMPARATOR
Intervention: non-selective NSAIDs (ibuprofen, diclofenac, or naproxen)
Number of subjects: 5441
Study: 12644728

Group type: EXPERIMENTAL
Intervention: 8‐epi‐prostaglandin F2 alpha (PGF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11379456

Group type: EXPERIMENTAL
Intervention: Three doses of the TSI-GSD 200 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One or two doses of the TSI-GSD 200 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haemagglutination inhibition (HI) test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plaque reduction neutralisation (PRN) test
Number of subjects: 0
Study: 8850763

Group type: EXPERIMENTAL
Intervention: Standard clinic instruction plus a voucher for a free mammogram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinic instruction alone
Number of subjects: 0
Study: 1531259

Group type: EXPERIMENTAL
Intervention: Phloroglucinol (40 mg, two ampoules)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (two ampoules)
Number of subjects: 20
Study: 4077795

Group type: EXPERIMENTAL
Intervention: Atropine aerosol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Buffered saline
Number of subjects: 8
Study: 31489020

Group type: EXPERIMENTAL
Intervention: Oral Labetalol
Number of subjects: 124

Group type: COMPARATOR
Intervention: Oral Nifedipine
Number of subjects: 124
Study: 29432326

Group type: EXPERIMENTAL
Intervention: Weight loss program + exercise program (WL + E group, n = 28)
Number of subjects: 55
Study: 26653014

Group type: EXPERIMENTAL
Intervention: Tailored SMS group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Non-tailored SMS group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 24778393

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 208
Study: 22449317

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 60
Study: 20086031

Group type: EXPERIMENTAL
Intervention: Linagliptin (10 mg, oral)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg, intravenous)
Number of subjects: 14
Study: 18044335

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (group I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Classic cholecystectomy (group II)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Planned laparoscopic cholecystectomy (control group)
Number of subjects: 80
Study: 18955380

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of iron
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous infusion of desferrioxamine
Number of subjects: 16
Study: 15468991

Group type: EXPERIMENTAL
Intervention: L-sulpiride (25 mg t.i.d. intravenously for 3 days, then orally for 7 days)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: L-sulpiride
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group treated with other vestibular suppressants
Number of subjects: 87
Study: 11585003

Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravesical bacillus Calmette‐Guerin (BCG)
Number of subjects: 0
Study: 9215023

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 20
Study: 7663466

Group type: EXPERIMENTAL
Intervention: Implant design, application, and site of placement
Number of subjects: 2132
Study: 3604933

Group type: EXPERIMENTAL
Intervention: Sonicated Renografin‐76 (1.5 to 2.0 ml)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nonsonicated Renografin‐76 (7 to 9 ml)
Number of subjects: 7
Study: 31421272

Group type: EXPERIMENTAL
Intervention: Selective digestive tract decontamination (SDD)
Number of subjects: 8665

Group type: EXPERIMENTAL
Intervention: Selective oropharyngeal decontamination (SOD)
Number of subjects: 8665

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 8665
Study: 30445275

Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Significant reductions in smoking
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Percent change in cigarettes smoked (modeled continuously)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Changes in alcohol use
Number of subjects: 150
Study: 27854559

Group type: EXPERIMENTAL
Intervention: Cyclic hormonal contraception (CHC)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Nonhormonal contraception
Number of subjects: 490
Study: 26109611

Group type: EXPERIMENTAL
Intervention: PLLA-HA screw
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium screw
Number of subjects: 40
Study: 25246774

Group type: EXPERIMENTAL
Intervention: Aminaphtone (Capilarema 75 mg) administered twice daily for 5 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo administered twice daily for 5 days
Number of subjects: 30
Study: 22047100

Group type: EXPERIMENTAL
Intervention: Errorless naming treatment (ENT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gestural facilitation of naming (GES)
Number of subjects: 8
Study: 19283886

Group type: EXPERIMENTAL
Intervention: HP-B (High Protein at Breakfast)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HP-L (High Protein at Lunch)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HP-D (High Protein at Dinner)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HP-E (High Protein Equally Divided)
Number of subjects: 9
Study: 17375492

Group type: EXPERIMENTAL
Intervention: Intervention dose (number of six possible intervention components completed)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Completion of four telephone counseling calls
Number of subjects: 1088
Study: 15726540

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 11916546

Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m(2) on day 1) plus 5-fluorouracil (1000 mg/m(2) continuous infusion for 4 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m(2) on day 1) plus 5-fluorouracil (1000 mg/m(2) continuous infusion for 4 days) plus alpha-interferon 2b (3 million Units/day subcutaneously from day 1 for 5 days)
Number of subjects: 36
Study: 9861120

Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms kg‐1 followed by 0.833 microgram kg‐1 min‐1 until dural closure (group Alf.)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms kg‐1 followed by 0.833 microgram kg‐1 min‐1 for 2 h, then remifentanil 0.25 microgram kg‐1 min‐1 (group Alf.-Remi.)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram kg‐1 followed by 0.5 microgram kg‐1 min‐1 reducing to 0.25 microgram kg‐1 min‐1 after craniotomy (group Remi.)
Number of subjects: 52
Study: 7630152

Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg orally (p.o.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dopamine 2 micrograms/kg/min intravenously (i.v.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dopamine 4 micrograms/kg/min intravenously (i.v.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dopamine 6 micrograms/kg/min intravenously (i.v.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine 6 micrograms/kg intravenously (i.v.)
Number of subjects: 13
Study: 2705719

Group type: EXPERIMENTAL
Intervention: Polybutester (Novafil, Davis & Geck)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTFE (Gore‐tex, W L Gore)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nylon (Ethilon, Ethicon UK)
Number of subjects: 0
Study: 937355

Group type: EXPERIMENTAL
Intervention: Morphine sulfate 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Meperidine hydrochloride 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pentazocine 60 mg
Number of subjects: 12
Study: 30682144

Group type: EXPERIMENTAL
Intervention: Elastic Tape (ET)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham Tape (ST)
Number of subjects: 13
Study: 28068440

Group type: EXPERIMENTAL
Intervention: Topography-guided custom ablation (TCAT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) ablation
Number of subjects: 30
Study: 25299740

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel filler augmentation of the tear trough
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hyaluronic acid gel augmentation of the cheek
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both tear trough and cheek treated
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both sides treated (tear trough and cheek)
Number of subjects: 12
Study: 23280399

Group type: EXPERIMENTAL
Intervention: Full AMIGAS program with video (n = 151)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: AMIGAS program without video (n = 154)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: AMIGAS program without flip chart (n = 155)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Usual care control group (n = 153)
Number of subjects: 613
Study: 21559801

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19120041

Group type: EXPERIMENTAL
Intervention: 30‐min supervised self‐study session
Number of subjects: 45

Group type: COMPARATOR
Intervention: 30‐min neonatal resuscitation session using the Zoe simulator
Number of subjects: 45
Study: 16957516

Group type: EXPERIMENTAL
Intervention: Budesonide treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 14742371

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl, alfentanil, sufentanil, remifentanil, buprenorphine, naloxone
Number of subjects: 0
Study: 11532487

Group type: EXPERIMENTAL
Intervention: Intergel solution (300 mL)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (control)
Number of subjects: 281
Study: 9448656

Group type: EXPERIMENTAL
Intervention: Bupropion SR (100‐300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline (50‐200 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0
Study: 7939468

Group type: EXPERIMENTAL
Intervention: LHRH agonist (Zoladex)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Oestrogen (polyoestradiol phosphate, Estradurin)
Number of subjects: 236
Study: 3374415

Group type: EXPERIMENTAL
Intervention: Continuing medical education (CME) in cardiovascular and cancer medicine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 31
Study: 31720933

Group type: EXPERIMENTAL
Intervention: Mitomycin (40 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Oxaliplatin (200 mg/m2)
Number of subjects: 121
Study: 31666152

Group type: EXPERIMENTAL
Intervention: Low dose (0.2 mg) IN SCOP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High dose (0.4 mg) IN SCOP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28069654

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Kanamycin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Number of subjects: 80
Study: 24664535

Group type: EXPERIMENTAL
Intervention: Endobronchial valves placement
Number of subjects: 0